This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the
efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or
radiographic evidence of sinusitis.
Eligible participants are randomized to receive either Erenumab or placebo by subcutaneous
injection once monthly for 6 months. Study duration is eight months which includes a 30 day
screening/lead-in period and 6 monthly treatment visits followed by a follow-up visit one
month following the last dose of study drug administration. Participants will be expected to
score on a scale of 1 to 10 their symptoms of facial pain/pressure, nasal congestion, and
rhinorrhea as well well as any rescue medicines taken for pain each day via a mobile app.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.